ADMA Biologics Believes It Can Resolve CRL Issues Quickly, Spring Review Possible
Shares of ADMA Biologics [NASDAQ:ADMA] fell more than 45% on [...]
By Bill Langbein|2018-12-28T10:31:02-05:00December 28th, 2018|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|Tags: ADMA, ADMA Biologics, PDUFA|
Shares of ADMA Biologics [NASDAQ:ADMA] fell more than 45% on [...]